Accueil   Appels à projets   Innovative Medicines Initiative - IMI 2

Innovative Medicines Initiative – IMI 2

L'Initiative sur les Médicaments Innovants - IMI2 (2014-2020) a ouvert plusieurs appels à propositions.

Les grandes lignes de l'appel à projets

Date d'ouverture : 9 Juillet 2014

Date de clôture : 16 Mars 2017

Dimension : Europe

Financement : IMI

Thématique(s) médiale(s) : Essais cliniques, Essais pré cliniques, Immunologie, Maladies auto-immunes, Maladies génétiques - rares, Maladies infectieuses - Infectiologie, Maladies inflammatoires, Maladies liées au CNS, Maladies métaboliques, Maladies orphelines, Micro et nano technologies, Oncologie, Santé animale, Santé humaine

Secteur(s) industriel(s) :

IMI 2014

IMI (Innovative Medicines Initiative) est un partenariat public-privé entre les industries pharmaceutiques membres de l'EFPIA (European Federation of Pharmaceutical Industries and Associations) et la Communauté Européenne. Son objectif est de soutenir financièrement les collaborations de recherche paneuropéennes dans le domaine des médicaments innovants afin d'en renforcer la sécurité et l'efficacité.

Dans le cadre de sa nouvelle programmation 2014-2020, IMI lance de nouveaux appels.

Pour en savoir plus sur IMI


Les thèmes proposés sont :

  • Call 1: Translational approaches to disease modifying therapy of type 1 diabetes mellitus (appel clos)
  • Call 1: Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy (appel clos)
  • Call 2: Ebola and other filoviral haemorrhagic fevers (appel clos)
  • Call 3:
    • Remote assessment of disease and relapse (RADAR) - CNS
    • Towards a quantitative biological approach for neuropsychiatry
    • Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
    • The consistency approach to quality control in vaccine manufacture
    • Pertussis vaccination research
    • Knowledge repository to enable patient focused medicine development
  • Call 4: 
    • Enabling Platform on Medicines Adaptive Pathways to Patients
  • Call 5:
    • Topic 1: Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies     
    • Topic 2: Diabetic kidney disease biomarkers (DKD-BM)
    • Topic 3: Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33
    • Topic 4: Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)  
    • Topic 5: Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: phased expansion study          
    • Topic 6: From ApoE biology to validated Alzheimer’s disease targets      


  • Call 6: clos le 12 Janvier 2016 – 17:00:00 Brussels time
    •  Development of Quantitative System Toxicology (QST) approaches to improve the understanding of the safety of new medicines
    • Establishing impact of RSV (respiratory syncytial virus) infection, resultant disease and public health approach to reducing the consequences

Topics under the Big Data for Better Outcomes programme:

    • Real World Outcomes Across the AD (Alzheimer’s disease) Spectrum (ROADS) to Better Care
    • Development of an outcomes-focused platform to empower policy makers and clinicians to optimise care for patients with haematologic malignancies
    • Télécharger le texte de l'appel


  • Call 7: clos le 17 Mars 2016 – 17:00:00 Brussels time
    • validation of translational imaging methods in drug safety assessment (TRISTAN)
    • identification of druggable targets modulating misfolded proteins in Alzheimer’s and Parkinson’s diseases ;
    • pathological neuron-glia interactions in neuropathic pain ;
    • dry age-related macular degeneration: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention ;
    • a comprehensive ‘paediatric preclinical POC platform’ to enable clinical molecule development for children with cancer.


  • Des actions de Coordination sur les BIG DATA vont être soutenue
    • coordination and support action (CSA) for the big data for better outcomes programme ;
    • increase access and use of high quality data to improve clinical outcomes in heart failure (HF), atrial fibrillation (AF), and acute coronary syndrome (ACS) patients.


  • Call 8: Appel ouvert (en continu)- plusieurs dates de dépôt: 16 Mars 2016, 15 Septembre 2016, 16 Mars 2017, 14 Septembre 2017, 15 Mars 2018
    • Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks


  • Call 9: clos
    • Addressing the clinical burden of Clostridium difficile infection (CDI): Evaluation of the burden, current practices and set-up of a European research platform (part of the IMI New Drugs for Bad Bugs (ND4BB) programme)
    • Development of immune tolerance therapies for the treatment of rheumatic diseases
    • Data quality in preclinical research and development
    • Next generation of electronic translational safety
    • Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD)
    • Joint influenza vaccine effectiveness studies


  • Call 10 : ouvert dès le 4 janvier jusqu'au 28 mars 2017
    • Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
    • How big data could support better diagnosis and treatment outcomes for prostate cancer
    • Improving the care of patients suffering from acute or chronic pain
    • Creation of a pan-European paediatric clinical trials network
    • Biomanufacturing 2020: Development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
    • Unlocking the solute carrier gene-family for effective new therapies
    • Enhanced patient voice in medicines lifecycle  - feedback wanted (see below)
    • Precision medicines approaches in autism spectrum disorders


Retrouvez tous les détails sur le site IMI.

Infoday & webinars :

Des webinars sont également régulièrement organisés pour vous aider à monter votre projet (en savoir plus). Pour en savoir plus sur les Webinars, cliquez ici.

IMI encourage vivement les PME, les organisations de patients, les autorités réglementaires, les équipes universitaires, de l'industrie, les hôpitaux et autres organisations ayant un intérêt dans les projets de l'IMI à participer aux webinars. Lyonbiopôle vous accompagne à l'Europe.


Retrouvez notre offre d'accompagnement à l'Europe ici.